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Biosimilars that were not compared in clinical trials
with the compound innovator are not true biosimilars
(biocopies) and are associated with risks that the
clinical rheumatologist should be aware of before
generalized use. This article comments on various
aspects surrounding the use of such biocopies in
clinical rheumatology.spondylitis, psoriatic arthritis, psoriasis, and, surprisingly,The introduction of targeted biologic therapies has revolu-
tionized the treatment of immune inflammatory arthritis
[1]. The use of such compounds has significantly im-
proved patient outcomes and decreased the need for sur-
gical procedures to repair damaged joints [2]. The use of
tumor necrosis factor (TNF) antagonists has proven suc-
cessful since their introduction in 1999. The worldwide
sales of etanercept, infliximab, and adalimumab have
reached over $20 billion (USD), and these medications are
constantly in the top-ten list of blockbuster drugs [3].
Some rheumatologists advocate that for patients with less
severe disease they be used earlier than more traditional
therapies for rheumatoid arthritis. However, pricing has
been a major drawback for such implementation because
of the negative impact on public health-care costs. In
Brazil, patients who failed treatment with conventional
therapy and have active disease have access to more
expensive medications to control their arthritis [4]. The
Ministry of Health spends over $600 million (USD) yearly
to provide access to biologics and this amount accounts
for over 50% of the available budget for free medications
to public health patients with chronic diseases. However,
there is great enthusiasm for patent expirations with the
expectation that the introduction of biosimilars will sub-
stantially reduce the burden to the public health system, a* Correspondence: morton@osite.com.br
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article, unless otherwise stated.similar reduction having occurred with the use of biosimi-
lars for erythropoietin [5-7].
The European Medicine Agency (EMA) has already
approved the first biosimilar version of infliximab from
Celltrion (Incheon, Korea) and Hospira (Lake Forest, IL,
USA) for rheumatoid arthritis, paving the road for less
expensive medications when they finally reach the market
in 2015. Also important was the EMA recommendation
for approval of the infliximab biosimilar for ankylosing
inflammatory bowel disease, in which the pathogenetic role
of TNF is still not fully understood [8-11]. Whether gastro-
enterologists will be comfortable with this ‘bridging’ strat-
egy remains to be seen. Outside of the European Union
and the US, the regulatory framework for biosimilars varies
considerably. Some countries adopted the World Health
Organization (WHO) guidelines, which are very similar to
those of the EMA. Canada has its own guidelines that
present minor differences with those of the US Food and
Drug Administration, but no approved biosimilar has been
approved in the US.
In some countries in Latin America, non-innovator bi-
ologics have been approved by using legislation in place
for synthetic copies of brand compounds (that is, without
comparative clinical studies with the innovator). There-
fore, these products cannot be considered biosimilars; ra-
ther, they are biocopies, also known as intended copies or
non-regulated biologics [12,13]. The first was Etanar in
Colombia; Etanar is a biocopy of etanercept manufactured
in China and licensed as a new biologic. The second prod-
ucts were biocopies of rituximab. Reditux, a biocopy man-
ufactured by the Indian company Dr. Reddy’s (Hyderabad,
India), is licensed in Ecuador, Peru, Chile, Bolivia, and
Paraguay. In Mexico, the local manufacturer, Probiomed
(Mexico City), commercialized a biocopy of rituximab
under the brand name Kikuzabam. In March 2014, owing
to several adverse events, this biocopy was withdrawn
from the market and its registration was nullified. More
recently, in Mexico, two biopsies of etanercept were intro-
duced in the market. One is the Chinese product which in; licensee BioMed Central Ltd. The licensee has exclusive rights to distribute this
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tam, produced by Probiomed. In Mexico, there is already
legislation that requires comparability trials with the
reference biologic, but the request for marketing these
products was introduced before the new regulation was
effective. Surprisingly, the Mexican biocopies have been
purchased at prices similar to those of the innovator
products [14]. Therefore, savings for the social security
system are minimal or non-existent. It appears that
what led the Mexican regulatory agency to cancel the
registration of the biocopy of rituximab was the frequent
occurrence of anaphylactic reactions when switching be-
tween the two commercialized rituximab products [15].
At present, there is automatic substitution of etanercept
and rituximab innovators and biocopies at the pharmacy
level, without the physician being informed which product
is actually dispensed. Moreover, Mexican biocopies may
be used in the US, as American citizens frequently pur-
chase their medication in Mexico because of its cheaper
prices [16]. From the above, the lack of a uniform ap-
proach to the regulatory approval of true biosimilars ver-
sus biocopies (intended copies) in Latin America is clear.
In Brazil, the risk of registration of biocopies is null
since the current legislation is similar to the recommen-
dations from the WHO and the EMA. The Brazilian
national agency (ANVISA) requests that a complete pre-
analytical dossier and a rigorous comparison with the
reference product be available. To stimulate the advent
of biosimilars, the Ministry of Health is sponsoring an
initiative known as Productive Partnership for Develop-
ment, which will lead to domestic production of biosimi-
lars through a transfer of technology agreement with
international companies that are developing production
of biosimilars, such as Sandoz (part of Novartis, Basel,
Switzerland), Samsung (Seoul, Korea), Samsung Bioepis
(Incheon, Korea), and Epirus Biopharmaceuticals, Inc.
(Boston, MA, USA). Merck Serono (Darmstadt, Germany)
has recently signed a partnership with a new Brazilian
company (Bionovis, Barueri, Brazil) to ensure transfer of
technology for the production of biosimilars during the
next 5 years. The rituximab product from Merck Serono
has yet to produce data of comparability in arthritis, a rea-
son for concern since the products available at present are
biocopies instead of true biosimilars. Orygen (Parkville,
Australia), another biotechnology company, has signed a
production partnership with Pfizer Inc. (New York, NY,
USA) for technology transfer of adalimumab, infliximab,
and rituximab.
In Europe, only biosimilars are expected to be ap-
proved and the risks of biocopies are avoided. How
rheumatologists will deal with the fact that approval of a
biosimilar was extended to all indications of Remicade
(Janssen, Horsham, PA, USA) although Celltrion and
Hospira undertook phase 1 and 3 studies in onlyrheumatoid arthritis and ankylosing spondylitis remains
to be seen.
The use of biocopies does not lead to the necessary
safety that is associated with the prescription of the in-
novator or a true biosimilar when they become licensed
for use in clinical practice. Owing to the absence of rigor-
ous clinical testing, biocopies should not be expected to
have almost identical efficacy. Another issue that can gen-
erate confusion in clinical practice is the heterogeneity
present in various countries in post-marketing surveil-
lance programs by the health agencies when biocopies are
exchanged with the innovator in an uncontrolled manner.
In addition, nomenclature terminology regarding the use
of the innovator versus biocopies is still an open issue
[6,7]. The lack of mechanisms to rapidly identify toxicity
issues, we believe, relates to the delay in the withdrawal of
the biocopy of rituximab in Mexico.
Finally, the gradual acceptance of the first true biosi-
milar by rheumatologists will depend on real-life expos-
ure. Norwegian authorities plan to address this issue
this year by funding a head-to-head study of Inflectra
(Hospira) (a biosimilar) versus Remicade in a bid to
convince rheumatologists to prescribe the biosimilar be-
cause of its similarities in efficacy and safety and cost
savings. The stimulation of switching back and forth by
the Norwegian health authorities has yet to be adopted
by any other country in Europe, and how this inter-
changeability approach will develop in the near future
remains to be seen [17].
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